A client comes in and tells you her part keeps getting wider. She’s noticed a little tenderness at the crown. Her mother had the same thing. Her aunt too. The hair there feels thinner, or maybe it’s just breaking, she’s not sure. She’s been relaxing her hair since she was eight. She’s wondering if it’s the chemicals. Or the heat. Or the tight ponytails. Or just stress.
If you work with Black women, this conversation happens constantly. And it is easy to miss what it actually is, because the surface story points to traction or breakage or pattern thinning. But the underlying process, if this is what I think it is, is a scarring alopecia that is permanently destroying follicles at the crown. The window to intervene is narrow. Miss it, and the follicle doesn’t come back.
Central centrifugal cicatricial alopecia (CCCA) is the most common primary scarring alopecia in women of African descent. For most of its clinical history it was attributed to hot combs, chemical relaxers, and tight braiding. The hair practices took the blame. The 2019 New England Journal of Medicine paper on PADI3 changed that narrative. Subsequent gene expression work at Johns Hopkins identified the fibroproliferative mechanism driving follicle loss. And the treatment research over the past three years is finally catching up to the biology. This is the current state of the evidence.
What CCCA Actually Is
CCCA is a lymphocyte-mediated primary scarring alopecia that begins at the vertex of the scalp and expands outward in a roughly circular pattern. The earliest histopathologic finding is premature desquamation of the inner root sheath, followed by perifollicular lymphocytic inflammation concentrated at the level of the isthmus and infundibulum. As the process continues, the follicle is destroyed and replaced by fibrous tracts. The outcome is permanent hair loss in the affected zone.
The clinical picture often looks deceptively ordinary in early disease. The crown appears slightly thinned, the part may widen, and the client frequently reports mild tenderness, tingling, or itching in the affected area. Many are told they have female pattern hair loss and handed a bottle of minoxidil. By the time the diagnosis is made, the scarring is often advanced and some portion of the follicle population is permanently gone. This is why CCCA remains one of the most commonly misdiagnosed conditions in the hair loss differential.
CCCA and female pattern hair loss can look similar at the vertex. The differentiator is scarring: loss of follicular ostia on close inspection, perifollicular erythema, and trichoscopic peripilar white halos point toward CCCA. If the ostia are preserved and there is hair diameter variability, lean toward AGA. When in doubt, biopsy.
The PADI3 Discovery: CCCA Has a Genetic Component
This landmark paper reframed how CCCA is understood. Using whole-exome sequencing on 16 women with biopsy-proven CCCA, the investigators identified loss-of-function variants in the PADI3 gene in 24% of the cases. PADI3 encodes peptidylarginine deiminase 3, an enzyme that citrullinates structural proteins, including trichohyalin, which are essential to the proper formation and mechanical integrity of the hair shaft and inner root sheath.
The biology connects cleanly to the histology. The earliest pathologic finding in CCCA is premature desquamation of the inner root sheath. If PADI3 function is impaired, the inner root sheath cannot form properly, and the follicle becomes structurally vulnerable. Mechanical stress, inflammation, and hair grooming practices that would not destroy a genetically normal follicle may push a PADI3-deficient follicle past its failure point.
This does not mean CCCA is purely genetic. 76% of the biopsied cases in the original paper did not carry identified PADI3 variants, and CCCA almost certainly involves multiple genes and environmental triggers. But the finding established that CCCA is not simply a consequence of styling practices. A genetic susceptibility is operating, and that susceptibility tracks in families, which matches what practitioners see clinically when clients report mothers, aunts, and grandmothers with similar central thinning.
Family history matters. When you take the hair history, ask specifically about mothers, grandmothers, and maternal aunts with central thinning, relaxer-related problems, or crown hair loss. A family pattern supports earlier biopsy and earlier aggressive intervention. The hair practices alone did not cause this. The genetics set the stage.
The Fibroproliferative Signature: What the Hopkins Lab Found
While the PADI3 paper explained a genetic predisposition, Crystal Aguh’s lab at Johns Hopkins explained the tissue-level mechanism. Using transcriptomic analysis on scalp biopsies from CCCA patients versus controls, the investigators identified preferential upregulation of fibroproliferative pathway genes, including genes involved in collagen deposition, transforming growth factor beta (TGF-β) signaling, and platelet-derived growth factor activity. The same gene signature is seen in organ-fibrosing conditions such as scleroderma and keloid scarring.
This finding matters for two reasons. It explains why CCCA looks on histology the way it does, with progressive replacement of follicular structures by dense fibrous connective tissue. And it opens a therapeutic pathway. If CCCA is fundamentally a localized fibrosing disorder, then anti-fibrotic agents that work in other connective tissue diseases may be useful here. That hypothesis is now being tested clinically.
The two-hit framework now widely cited in the CCCA literature combines these findings: an inherited vulnerability in the follicular structure itself (PADI3 and likely other genes) is compounded by an inflammatory trigger that initiates follicular injury, and a fibroproliferative response that fixes the damage as permanent scar. Styling practices did not invent the disease, but they can serve as one of the injury triggers in a follicle that is already structurally compromised.
Metformin: An Unexpected Candidate
This is where the fibroproliferative framework produced an actionable hypothesis. Metformin, the first-line oral diabetes medication, has well-documented anti-fibrotic activity in preclinical models of pulmonary fibrosis, cardiac fibrosis, and systemic sclerosis. It acts in part by activating AMP-activated protein kinase (AMPK) and inhibiting the TGF-β signaling cascade that drives fibroblast activation.
Aguh’s team reported a case series of CCCA patients treated with compounded topical metformin 10% applied to the affected scalp. The published cohort demonstrated clinical improvement in inflammation, texture, and, in some patients, regrowth in areas that had previously appeared stable. The authors are careful to frame this as early signal, not a validated standard of care, but the mechanistic fit is clean and the clinical observations are meaningful. Larger prospective studies are ongoing, and compounded metformin is now being prescribed in specialty hair clinics where prior anti-inflammatory regimens have plateaued.
Topical metformin is not FDA-approved for CCCA. It is a compounded preparation prescribed off-label by dermatologists who manage CCCA. Evidence is early but mechanistically compelling. Practitioners who see CCCA should know this exists so they can refer patients to physicians equipped to consider it when conventional regimens stall.
Trichoscopy: The Single Most Useful Non-Invasive Tool
Trichoscopy in CCCA has specific, reproducible findings that separate it from female pattern hair loss and from other scarring alopecias. The dominant features are peripilar white or gray halos surrounding emergent hair shafts, reflecting perifollicular fibrosis at the upper dermis. A 2016–2020 literature consensus, repeatedly validated in subsequent studies, positions peripilar halos as the most specific early trichoscopic sign of CCCA.
Additional features include loss of follicular openings in affected zones (the ostia that should be present on close inspection are gone), pinpoint white dots in advanced disease, irregular honeycomb pigment patterns on the interfollicular scalp, and perifollicular erythema at actively inflamed sites. The hair shafts themselves are usually not miniaturized. Diameter is largely preserved until follicular dropout occurs, which is another differentiator from AGA where miniaturization precedes loss.
A 2023 update in the trichoscopy literature emphasized that the earliest phase of CCCA, before frank alopecia is visible, can show peripilar halos alone in an otherwise normal-appearing crown. If you are scoping a client who has family history, subtle tenderness, or a vague sense that the crown is changing, and you see halos, do not wait. That is a biopsy conversation.
The Biopsy Question: When and What to Ask For
A 4-mm punch biopsy taken from an actively inflamed or transition-zone area, sent for horizontal and vertical sections, remains the diagnostic gold standard. The early histologic findings, again, are premature desquamation of the inner root sheath, concentric perifollicular lymphocytic inflammation at the isthmus, and early perifollicular fibrosis. As the disease progresses, the terminal follicle is lost, the arrector pili can be preserved as a ghost structure, and dense fibrotic tracts replace the follicular unit.
Practitioners in trichology practice often work alongside dermatologists who order and interpret biopsies. The message to deliver when referring is specific: you are asking for evaluation for primary scarring alopecia, CCCA pattern, and you are asking the pathologist to look specifically for premature inner root sheath desquamation and perifollicular lymphocytic inflammation. A generic biopsy read without that context can miss early CCCA because the classic late findings are not yet present.
Current Management: What the 2023–2025 Evidence Supports
The 2023 updated review from the Hopkins group and collaborators synthesizes the current management framework. Treatment is organized around three parallel goals: suppress the inflammation driving active follicle loss, modulate the fibroproliferative response shaping the permanent damage, and support regrowth where follicles remain salvageable.
First-line anti-inflammatory management remains high-potency topical corticosteroids (clobetasol 0.05% or equivalent), often combined with intralesional triamcinolone acetonide at 5–10 mg/mL injected into active margins every 4–6 weeks. These should be prescribed and administered by a dermatologist. Oral doxycycline at sub-antimicrobial anti-inflammatory dosing (20–40 mg twice daily) is commonly added for its tetracycline-class anti-inflammatory effects and matrix metalloproteinase inhibition.
Hydroxychloroquine at standard rheumatologic dosing is reserved for cases with prominent inflammation that have failed first-line management. Oral and intralesional therapies, when effective, are typically continued for 6–12 months before tapering. Minoxidil (topical 5% solution or foam, sometimes combined with low-dose oral minoxidil where appropriate) is frequently added to support regrowth in salvageable follicles; it does not treat the scarring process but can improve density in non-scarred adjacent zones.
The emerging additions to this framework over the past two years include topical metformin 10% compounded preparations, as discussed, and selective use of platelet-rich plasma in non-inflamed, stabilized CCCA to support follicles in the transition zone. Anti-TGF-β investigational therapies and JAK inhibitor trials for scarring alopecia are in earlier stages of development and may reshape the paradigm within the next several years.
The Hair Practice Conversation, Done Correctly
For decades, CCCA was attributed almost entirely to relaxers, hot combs, tight braiding, and heavy styling products. The PADI3 and fibroproliferative data reframed the picture: this is a genetically influenced fibrosing disorder, and hair practices alone are not the cause. But some practices can serve as inflammatory triggers in an already vulnerable follicle, and modifying them is part of responsible management.
What the evidence supports, pragmatically: avoid tension styling on the affected crown, defer chemical relaxers while the follicle is under inflammatory attack, minimize prolonged heat directly on the vertex, and avoid styling practices that cause tenderness or burning sensation. What the evidence does not support: shame or blame for past styling choices. That framing has caused real harm to clients who were told their hair loss was their fault and walked away from care. It also misses the underlying biology.
For stylists, this is the most important clinical conversation: you are seeing the scalp before the dermatologist does. You are often the first person to notice that a client’s crown is changing, that there is tenderness on shampoo, that the part is widening. A referral at that stage, before the scarring is visible to the naked eye, may be the single most consequential intervention in that client’s hair loss trajectory.
When you notice early signs, tenderness in the crown, peripilar halos on the scope, subtle widening of the part, a client who mentions her mother had something similar, do not wait to see if it gets worse. The window for pharmacologic rescue is narrowest in the earliest disease. Refer to a dermatologist experienced with scarring alopecias. Put the biopsy question on the table.
What This Means for Your Practice
Family history is diagnostic information. CCCA has a genetic component that tracks in families. When a new client reports central thinning and mentions female relatives with the same pattern, that history alone shifts your index of suspicion. Document it. Use it to argue for earlier referral.
The earliest finding is peripilar halos, not visible hair loss. A trichoscope is not optional in this work. If you are assessing a client at risk, scope the crown. If you see halos, act on them. Do not wait until the thinning is visible in a mirror.
Do not assume minoxidil will solve it. CCCA and FPHL can look similar at the vertex, and minoxidil is often the default response. Minoxidil does not stop a scarring process. If a client has been on minoxidil for six months and the area still feels tender, the diagnosis needs to be revisited.
Biopsy earlier rather than later. The definitive diagnosis changes the treatment entirely. Primary scarring alopecia is managed differently than non-scarring hair loss. Do not hesitate to recommend a punch biopsy to the referring physician when the clinical picture and trichoscopy point in this direction.
Remove the blame from the conversation. The PADI3 and fibroproliferative data are not just academic findings. They reshape how you speak to a client who has internalized decades of messaging that her hair loss is her own fault. The biology is more complex, the genetics are real, and the client deserves to hear that clearly.
Know the treatment options so you can speak about them credibly. Clobetasol, intralesional triamcinolone, sub-antimicrobial doxycycline, hydroxychloroquine in refractory cases, topical minoxidil to support adjacent follicles, and increasingly, compounded topical metformin as an anti-fibrotic. You are not prescribing these. You are helping your clients understand the treatment ladder so they can advocate for appropriate care.
The Bottom Line
CCCA is not caused by relaxers. It is not caused by tight styles. It is a genetically influenced, lymphocyte-mediated, fibroproliferative scarring alopecia with a narrow window for pharmacologic intervention before the follicles are permanently lost. The 2019 NEJM paper established a PADI3 susceptibility in 24% of biopsied cases. The Hopkins transcriptomic work mapped a fibroproliferative signature that opened the door to anti-fibrotic therapy, most notably compounded topical metformin. The 2023–2025 management updates reinforce a multipronged approach: suppress inflammation with potent topical and intralesional corticosteroids plus sub-antimicrobial doxycycline, modulate the fibrotic response when available, support regrowth in salvageable follicles, and refer early. The most valuable thing a trichologist or stylist can do is recognize the peripilar halos, hold a clear-eyed conversation about what is actually happening, and get the client to appropriate care before the window closes.